Loading...
•
Sep 30, 2024
Editas Q3 2024 Earnings Report
Editas Medicine reported a net loss for Q3 2024 and provided business updates, including preclinical proof of concept of HBG1/2 editing in HSPCs.
Key Takeaways
Editas Medicine reported a net loss of $62.1 million, or $0.75 per share, for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities were $265.1 million as of September 30, 2024. They achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs).
Achieved in vivo preclinical proof of concept of HBG1/2 editing in HSPCs using Editas Medicine’s proprietary targeted LNP.
On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at ASH in December.
Company to provide an update on its in vivo progress and pipeline development in 1Q 2025.
Existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditures into the second quarter of 2026.
Revenue by Segment
Forward Guidance
Editas Medicine expects existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI and the retained portions of the payments payable under the license agreement with Vertex, to fund operating expenses and capital expenditures into the second quarter of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...